You are here

Article Text

Article menu
Download PDFPDF
Letter
Safety and efficacy of TNFα blockade in relapsing vasculitis
  1. A D Booth1,
  2. H J Jefferson2,
  3. W Ayliffe3,
  4. P A Andrews2,
  5. D R Jayne1
  1. 1Department of Medicine, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
  2. 2SW Thames Renal and Transplantation Unit, St Helier Hospital, Carshalton SM1 AA, UK
  3. 3Mayday University Teaching Hospital, Croydon CR7 7YE, UK
  1. Correspondence to:
    Dr A D Booth, Department of Renal Medicine, Box No 118, Addenbrooke's NHS Trust, Hills Road, Cambridge CB2 2QQ, UK;
    tonybooth1{at}yahoo.co.uk

https://doi.org/10.1136/ard.61.6.559

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Blockade of tumour necrosis factor alpha (TNFα) using infliximab, a chimeric monoclonal antibody against TNFα, is an effective treatment in rheumatoid arthritis and Crohn's disease.1, 2 Sifikakis reported success using infliximab in sight threatening Behçet's disease.3 A preliminary study has also reported clinical improvements in the primary systemic vasculitis, Wegener's granulomatosis, with the soluble TNFα receptor etanercept.4 The benefit of lenercept, a soluble p55 TNFα receptor fusion protein, on digital vasculitis in rheumatoid arthritis has also …

    View Full Text